Different thallium-201 single-photon emission tomographic patterns in benign and aggressive meningiomas
- PMID: 8854846
- DOI: 10.1007/BF01254472
Different thallium-201 single-photon emission tomographic patterns in benign and aggressive meningiomas
Abstract
To evaluate the possibility of preoperatively obtaining an index of aggressiveness for intracranial meningiomas, we prospectively studied 22 patients with computed tomographic or magnetic resonance imaging evidence of meningeal tumour, using single-photon emission tomography (SPET) of the brain and thallium-201 (201Tl). On a brain-dedicated SPET scanner, a rapid acquisition protocol with early, short scans was started simultaneously with the intravenous administration of 111 MBq 201Tl, covering the initial intratumoral distribution of the tracer. Twenty minutes post injection, a delayed SPET scan was also obtained. On the reconstructed and attenuation-corrected images we calculated the 201Tl concentration in tumour and normal contralateral brain tissue, and compared intratumoral tracer concentration in the initial and the final part of the rapid acquisition protocol. Benign and malignant meningiomas were classified as such based on histological examination. In malignant lesions, the ratio of the 201Tl concentration at 2-4 min post injection to that at 14-16 min was found to be significantly higher than in non-aggressive neoplasms (mean+/-1 SD: 1.14+/-0.31 and 0.56+/-0.13, respectively, P <0.01). Conversely, in the delayed scan, most lesions showed high tracer concentration, and the two groups could not be distinguished. In addition, three recurrent meningiomas displayed the same imaging behaviour as the malignant group, i.e. had similar 201Tl concentration values at 2-4 and at 14-16 min. Our findings suggest that the comparative assessment of intratumoral 201Tl concentration at 2-4 and at 14-16 min post injection could provide a fast, simple method to differentiate preoperatively intracranial meningiomas with different biological behaviour.
Similar articles
-
Thallium-201 SPECT for predicting histological types of meningiomas.J Nucl Med. 1993 Dec;34(12):2091-4. J Nucl Med. 1993. PMID: 8254393
-
Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours.Eur J Nucl Med. 1994 Jul;21(7):621-33. doi: 10.1007/BF00285584. Eur J Nucl Med. 1994. PMID: 7957348
-
Tumour-like thallium-201 accumulation in brain infarcts, an unexpected finding on single-photon emission tomography.Eur J Nucl Med. 1994 Mar;21(3):191-5. doi: 10.1007/BF00188664. Eur J Nucl Med. 1994. PMID: 8200385
-
Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: comparison with thallium-201 imaging.J Nucl Med. 1998 May;39(5):802-6. J Nucl Med. 1998. PMID: 9591579
-
[Recurrent meningiomas with progressive aggressiveness and posterior extracranial extension].Neurocirugia (Astur). 2003 Oct;14(5):409-16. doi: 10.1016/s1130-1473(03)70520-x. Neurocirugia (Astur). 2003. PMID: 14603388 Review. Spanish.
Cited by
-
Usefulness of thallium-201 SPECT in the evaluation of tumor natures in intracranial meningiomas.Neuroradiology. 2011 Nov;53(11):867-73. doi: 10.1007/s00234-010-0822-2. Epub 2011 Jan 8. Neuroradiology. 2011. PMID: 21221558
-
SPECT and PET imaging of meningiomas.ScientificWorldJournal. 2012;2012:412580. doi: 10.1100/2012/412580. Epub 2012 May 1. ScientificWorldJournal. 2012. PMID: 22623896 Free PMC article.
-
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis.Quant Imaging Med Surg. 2017 Oct;7(5):592-597. doi: 10.21037/qims.2017.06.09. Quant Imaging Med Surg. 2017. PMID: 29184769 Free PMC article.
-
Grading meningioma: a comparative study of thallium-SPECT and FDG-PET.Medicine (Baltimore). 2015 Feb;94(6):e549. doi: 10.1097/MD.0000000000000549. Medicine (Baltimore). 2015. PMID: 25674763 Free PMC article.
-
(99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index.J Neurooncol. 2008 Sep;89(2):225-30. doi: 10.1007/s11060-008-9611-8. Epub 2008 May 6. J Neurooncol. 2008. PMID: 18458817